Hydralazine-Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis.

ABSTRACT:

Introduction

The combination of hydralazine-isosorbide dinitrate (H-ISDN) has potential as a heart failure (HF) therapy in the setting of maintenance dialysis.

Methods

In this retrospective study, we analyzed the efficacy of H-ISDN using United States Renal Data System (USRDS) data. We identified all adult patients with a history of HF on maintenance dialysis between January 1, 2011, and December 31, 2016, with at least 1 prescription for H-ISDN. Baseline characteristics, prescriptions, and outcomes were retrieved from institutional and physician claims. The primary outcome was death from any cause. Additional outcomes included cardiovascular death, sudden cardiac death, hospitalization for HF, an inpatient diagnosis of myocardial infarction (MI), or new-onset atrial fibrill

SUBMITTER: Mavrakanas TA 

PROVIDER: S-EPMC9171697 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature